Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Progress in improving the pathogen safety of red cell concentrates
Autore:
Chapman, J;
Indirizzi:
VI Technol VITEX, Blood Prod Res, Watertown, MA 02472 USA VI Technol VITEX Watertown MA USA 02472 Prod Res, Watertown, MA 02472 USA
Titolo Testata:
VOX SANGUINIS
, volume: 78, anno: 2000, supplemento:, 2
pagine: 203 - 204
SICI:
0042-9007(2000)78:<203:PIITPS>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
6
Recensione:
Indirizzi per estratti:
Indirizzo: Chapman, J VI Technol VITEX, Blood Prod Res, 134 Coolidge Ave, Watertown, MA 02472 USA VI Technol VITEX 134 Coolidge Ave Watertown MA USA 02472 72 USA
Citazione:
J. Chapman, "Progress in improving the pathogen safety of red cell concentrates", VOX SANGUIN, 78, 2000, pp. 203-204

Abstract

Current methods of preparing red cell concentrates do not include a process step to decontaminate pathogens potentially present in the transfusion product. Although substantial progress has been made in the reduction of the frequency of transmission of HIV, HCV, HBV and HTLV-I as a result of the implmentation of diagnostic screening processes, the need for further reduction in transmission rate of these viruses remains. In addition, there are viruses which are known to be be present in blood but for which no screening test has been implemented to remove contaminated units from the blood supply. These viruses include but are not limited to TTV, HGV and Parvo B19. Finally, the lack of a pathogen inactivation process for red cells maintains the blood supply in a state of vulnerability to new viruses or virus variants as they enter the donor population. Recently, substantial progress has been made in the research and development of a class of chemical compounds designated as INACTINE(TM). These compounds are being investigated for their potential to inactivate viruses in red cells without adversely affecting their physiologic function. One of the INACTINE(TM) compounds, designated as PEN110, is now in the clinical trial phase of development.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/07/20 alle ore 01:12:00